The Outcome of Chemoreduction Treatment in Patients With Reese-Ellsworth Group V Retinoblastoma | Pediatric Cancer | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Ellsworth  RM The practical management of retinoblastoma.  Trans Am Ophthalmol Soc. 1969;67462- 534Google Scholar
Shields  JAShields  CL Intraocular Tumors: A Text and Atlas.  Philadelphia, Pa WB Saunders Co1992;305- 391
White  L Chemotherapy for retinoblastoma: where do we go from here?  Ophthalmic Paediatr Genet. 1991;12115- 130Google ScholarCrossref
Goble  RRMcKenzie  JKingston  JEPlowman  PNHungerford  JL Orbital recurrence of retinoblastoma successfully treated by combined therapy.  Br J Ophthalmol. 1990;7497- 98Google ScholarCrossref
Pratt  CBFontanesi  JChenaille  P  et al.  Chemotherapy for extraocular retinoblastoma.  Pediatr Hematol Oncol. 1994;11301- 309Google ScholarCrossref
Doz  FKhelfaoui  FMosseri  V  et al.  The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients.  Cancer. 1994;74722- 732Google ScholarCrossref
O'Brien  JMSmith  BJ Chemotherapy in the treatment of retinoblastoma.  Int Ophthalmol Clin. 1996;3611- 24Google ScholarCrossref
Gallie  BLBunding  ADeBoer  G  et al.  Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy.  Arch Ophthalmol. 1996;1141321- 1328Google ScholarCrossref
Shields  CLDe Potter  PHimmelstein  BShields  JAMeadows  AMaris  J Chemoreduction in the initial management of intraocular retinoblastoma.  Arch Ophthalmol. 1996;1141330- 1338Google ScholarCrossref
Kingston  JEHungerford  JLMadreperla  SAPlowman  PN Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma.  Arch Ophthalmol. 1996;1141339- 1343Google ScholarCrossref
Murphree  ALVillablanca  JGDeegan  WF  et al.  Chemotherapy plus local treatment in the management of intraocular retinoblastoma.  Arch Ophthalmol. 1996;1141348- 1356Google ScholarCrossref
Greenwald  MJStrauss  LC Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy.  Ophthalmology. 1996;1031989- 1997Google ScholarCrossref
Shields  CLShields  JANeedle  M  et al.  Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.  Ophthalmology. 1997;1042101- 2111Google ScholarCrossref
Rubin  CMRobinson  LLCameron  JD  et al.  Intraocular retinoblastoma group V: an analysis of prognostic factors.  J Clin Oncol. 1985;3680- 685Google Scholar
Ellsworth  RM Retinoblastoma.  Mod Probl Ophthalmol. 1977;1894- 100Google Scholar
Abramson  DHEllsworth  RMTretter  P  et al.  Simultaneous bilateral radiation for advanced bilateral retinoblastoma.  Arch Ophthalmol. 1981;991763- 1766Google ScholarCrossref
Hungerford  JLToma  NMGPlowman  PNKingston  JE External beam radiotherapy for retinoblastoma, I: whole eye technique.  Br J Ophthalmol. 1995;79109- 111Google ScholarCrossref
Shields  CLShields  JADe Potter  PHimmelstein  BPMeadows  AT The effect of chemoreduction on retinoblastoma-induced retinal detachment.  J Pediatr Ophthalmol Strabismus. 1997;34165- 169Google Scholar
Wong  FLBoice  JDAbramson  DH  et al.  Cancer incidence after retinoblastoma: radiation dose and sarcoma risk.  JAMA. 1997;2781262- 1267Google ScholarCrossref
Tucker  MAD'Angio  GJBoice  JD  Jr  et al.  Bone sarcomas linked to radiotherapy and chemotherapy in children.  N Engl J Med. 1987;317588- 593Google ScholarCrossref
Roarty  JDMcLean  IWZimmerman  LE Incidence of second neoplasms in patients with bilateral retinoblastoma.  Ophthalmology. 1988;951583- 1587Google ScholarCrossref
Winick  NJMcKenna  RWShuster  JJ  et al.  Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.  J Clin Oncol. 1993;11209- 211Google Scholar
Abramson  DHFrank  CM Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk.  Ophthalmology. 1998;105573- 580Google ScholarCrossref
O'Brien  JM Alternative treatment in retinoblastoma.  Ophthalmology. 1998;105571- 572Google ScholarCrossref
Doz  FNeuenschwander  SPlantaz  D  et al.  Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d'Oncologie Pediatrique.  J Clin Oncol. 1995;13902- 909Google Scholar
Clinical Sciences
December 1998

The Outcome of Chemoreduction Treatment in Patients With Reese-Ellsworth Group V Retinoblastoma

Author Affiliations

From the Oncology Service, Wills Eye Hospital, Thomas Jefferson University (Drs Gündüz, C. L. Shields, J. A. Shields, Gross, and Cater), and the Children's Hospital of Philadelphia (Drs Meadows and Needle), Philadelphia, Pa.

Arch Ophthalmol. 1998;116(12):1613-1617. doi:10.1001/archopht.116.12.1613

Objective  To determine the outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.

Methods  Prospective analysis of 27 eyes in 22 patients with group V retinoblastoma treated with either 2- or 6-cycle chemoreduction and focal treatment methods (argon laser photocoagulation, transpupillary thermotherapy, cryotherapy, and plaque radiotherapy). The need for external beam irradiation and the eventual globe salvage rate were assessed. Median follow-up was 28 months.

Results  There were 16 eyes in the 2-cycle chemoreduction treatment group and 11 eyes in the 6-cycle chemoreduction treatment group. No significant difference was noted between the 2 groups with respect to baseline patient and eye findings. After chemoreduction treatment, external beam irradiation was necessary in 12 (75%) of 16 eyes in the 2-cycle chemoreduction treatment group and in 4 (36%) of 11 eyes in the 6-cycle chemoreduction treatment group. There was no statistical difference between the 2- and 6-cycle chemoreduction treatment groups with respect to necessity for external beam irradiation (logistic regression analysis). All 4 eyes in the 2-cycle chemoreduction treatment group and 3 of 12 eyes in the 2-cycle chemoreduction treatment and irradiation group were eventually enucleated, the globe salvage rates being 0% and 75%, respectively. Two of 7 eyes in the 6-cycle chemoreduction treatment group and 1 of 4 eyes in the 6-cycle chemoreduction treatment and irradiation group were enucleated, the globe salvage rates being 71% and 75%, respectively. Except for the 2-cycle chemoreduction treatment group, in which the globe salvage rate was significantly lower (P=.03), there was no difference among the other 3 groups (2-cycle chemoreduction treatment and irradiation, 6-cycle chemoreduction treatment, and 6-cycle chemoreduction treatment and irradiation) with respect to globe salvage (logistic regression analysis).

Conclusions  Local tumor control of group V retinoblastoma is possible with 6-cycle chemoreduction and focal therapy when external beam irradiation is not used. A larger sample size is necessary to determine how often external beam irradiation can be avoided.